The FDA has approved the sBLA for once every 4 weeks lecanemab-irmb (Leqembi®) intravenous maintenance dosing.

MALVERN, Pa. - Annovis Bio Inc. (NYSE: ANVS), a clinical-stage drug platform company trading near its 52-week low of $2.99, has announced the initiation of a Phase 3 trial for its Alzheimer's disease ...

The Washington University trial comes as part of a larger platform study, which hopes to understand whether the disease can ...

Delayed REM sleep may be linked to a higher risk of Alzheimer’s disease, new research found. Here's how to build a healthy sleep routine.

II-73, has the potential to restore memory and cognitive function in a mouse model of Alzheimer's disease. The study demonstrates that the drug improves memory deficits and reverses brain cell damage, ...

A paradigm-shifting study from the Centre for Addiction and Mental Health (CAMH) shows an experimental drug, GL-II-73, has the potential to restore memory and cognitive function in a mouse model of ...

An international research team has identified key genetic factors that confer protective effects against Alzheimer's disease (AD) through a comprehensive genetic analysis of East Asian populations, ...

Social activity not only delays dementia onset an average of five years; it also carries a $500,000 lifetime savings on healthcare costs per person, according to a new paper from Rush University ...

A new study showed that people who took longer to enter this dream phase of sleep had higher levels of amyloid beta and tau, ...

An international research team led by the Hong Kong University of Science and Technology (HKUST) has identified key genetic ...

Prehospital hypoxia, hypotension, and hypocarbia each were associated with poor outcomes after traumatic brain injury, ...

The virtual presentation is hosted by the Alzheimer’s Association and North Dakota State University Extension.